Skip to main content
Susana Campos on Muck Rack

Susana Campos

As seen in: Nature, Wiley Online Library, MDPI, Medscape, Emerald Publishing, Dialnet - Universidad de La Rioja, Cult Beauty, OncLive, Journal of Intellectual Capital, Targeted Oncology
https://www.facebook.com/

Get in touch with Susana

Contact Susana, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Data Updates Shift Treatment Standards in Gyn-Oncology

|
By Susana Campos
| Medscape Verified
This transcript has been edited for clarity. Good morning, everyone. My name is Susana Campos. I’m a medical oncologist at Dana-Farber Cancer Institute. Thank you for joining me today. Over the next 20 minutes, we will review the most important gynecological oncology updates from ASCO 2026. Today’s topics span three disease areas: endometrial cancer, ovarian cancer, and cervical cancer.
Open in Who Shared Issue with article?

Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial

|
By Rebecca Porter, Yinglu Zhou, Nebiyat Eskndir, Martin Hayes, Madeline Polak, Elizabeth Lee, Carolyn Krasner, Susana Campos, Alexi A. Wright, Joyce Liu, Elizabeth Stover, Hannah Sawyer, Niya Xiong, Kathleen L. Pfaff, Scott J. Rodig, Nabihah Tayob, Susan Zweizig, Veena John, Ursula Matulonis, Panagiotis A. Konstantinopoulos, Jennifer Veneris
| Nature Verified
Abstract Immune checkpoint inhibitors (ICI) synergize preclinically with antibody drug conjugates (ADC), harboring anti-tubulin maytansinoid payloads. We conducted an investigator-initiated, single-arm, phase 2 trial of mirvetuximab soravtansine (MIRV), a folate receptor alpha (FOLR1/FRα)-targeting ADC with the maytansinoid payload, DM4, combined with pembrolizumab in female patients with recurrent FOLR1-expressing serous endometrial cancer (EC, NCT03835819).
Open in Who Shared Issue with article?

Maintenance therapy after first‐line therapy for ovarian cancer: Quantitative effectiveness

|
By Susana Campos, Jessica DiSilvestro MD
| Wiley Online Library Verified
For patients with ovarian, peritoneal, and fallopian tube carcinoma, completing first-line treatment, maintenance therapy aims to stave off the risk of recurrence with the hope it will improve overall survival.
Open in Who Shared Issue with article?
See all 9 licensed articles (35 Total)